Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company’s equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Reported DateTime | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | Filing |
2024-01-31 2:08 pm Purchase | 13G | CITIUS PHARMACEUTICALS INC CTXR | BlackRock Inc. BLK | 8,457,814 5.3% | 6,110,522 (+260.32%) | View |
2022-07-08 4:56 pm Sale | 13G | CITIUS PHARMACEUTICALS INC CTXR | BlackRock Inc. BLK | 2,347,292 1.6% | -5,780,964 (-71.12%) | View |
2022-02-18 4:31 pm Purchase | 13D | CITIUS PHARMACEUTICALS INC CTXR | Mazur Leonard L | 18,092,136 11.76% | 7,017,963 (+63.37%) | View |
2022-02-18 4:30 pm Purchase | 13D | CITIUS PHARMACEUTICALS INC CTXR | HOLUBIAK MYRON Z | 3,864,604 2.61% | 1,715,368 (+79.81%) | View |
2022-02-14 6:44 pm Sale | 13G | CITIUS PHARMACEUTICALS INC CTXR | ARMISTICE CAPITAL LLC | 2,425,000 1.6% | -3,743,361 (-60.69%) | View |
2022-02-04 4:12 pm Purchase | 13G | CITIUS PHARMACEUTICALS INC CTXR | BlackRock Inc. BLK | 8,128,256 5.6% | 8,128,256 (New Position) | View |
2021-02-16 3:00 pm Purchase | 13G | CITIUS PHARMACEUTICALS INC CTXR | ARMISTICE CAPITAL LLC | 6,168,361 9.99% | 2,957,434 (+92.11%) | View |
2020-02-14 3:25 pm Purchase | 13G | CITIUS PHARMACEUTICALS INC CTXR | ARMISTICE CAPITAL LLC | 3,210,927 9.99% | 1,317,437 (+69.58%) | View |
2020-02-06 2:58 pm Sale | 13G | CITIUS PHARMACEUTICALS INC CTXR | DRILL CRAIG A | 693,600 2.4% | -860,900 (-55.38%) | View |
2019-05-28 1:39 pm Purchase | 13G | CITIUS PHARMACEUTICALS INC CTXR | DRILL CRAIG A | 1,554,500 7% | 754,500 (+94.31%) | View |